Recent advances in the treatment of gastrointestinal stromal tumors

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 3, 2014, Pages 115-127

  Serrano, César ^a   George, Suzanne ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

c KIT; gastrointestinal stromal tumors; imatinib; masitinib; nilotinib; regorafenib; sorafenib; sunitinib

Indexed keywords

ABELSON KINASE; BUPARLISIB; DASATINIB; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; LUMINESPIB; MASITINIB; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PAZOPANIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; REGORAFENIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUCCINATE DEHYDROGENASE; SUNITINIB; TRANSCRIPTION FACTOR ER81;

ADVANCED CANCER; CANCER CONTROL; CANCER INHIBITION; CANCER SURVIVAL; COMPLEX II DEFICIENCY; DISEASE COURSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FAILURE FREE SURVIVAL; FOOD AND DRUG ADMINISTRATION; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HEALTH CARE QUALITY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84898994085     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014522491     Document Type: Review

References (81)

1. Antonescu CR. Besmer P. Guo T. Arkun K. Hom G. Koryotowski B. et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 11, 4182–4190.
2. Bantscheff M. Eberhard D. Abraham Y. Bastuck S. Boesche M. Hobson S. et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol, 25, 1035–1044.
3. Bauer S. Duensing A. Demetri GD. Fletcher JA. (2007) KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene, 26, 7560–7568.
4. Bauer S. Yu LK. Demetri GD. Fletcher JA. (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res, 66, 9153–9161.
5. Debiec-Rychter M. Cools J. Dumez H. Sciot R. Stul M. Mentens N. et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC 412 inhibitor against imatinib-resistant mutants. Gastroenterology, 128, 270–279.
6. Blanke CD. Demetri GD. von Mehren M. Heinrich MC. Eisenberg B. Fletcher JA. et al. (2008 a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol, 26, 620–625.
7. Blanke CD. Rankin C. Demetri GD. Ryan CW. von Mehren M. Benjamin RS. et al. (2008 b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26, 626–632.
8. Blay JY. Shen L. Kang YK. Rutkowski P. Qin S. Nosov D. et al. Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 31, 2013 (suppl; abstr 10501). http://meetinglibrary.asco.org/content/117861-132.
9. Casali PG. Le Cesne A. Poveda A. Kotasek D. Rutkowski P. Hohenberger P. et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin Oncol 31, 2013 (suppl; abstr 10500). http://meetinglibrary.asco.org/content/114179-132.
10. Cassier PA. Fumagalli E. Rutkowski P. Schoffski P. Van G.M. Debiec-Rychter M. et al. (2012) Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res, 18, 4458–4464.
11. Cauchi C. Somaiah N. Engstrom PF. Litwin S. Lopez M. Lee J. et al. (2012) Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol, 69, 977–982.
12. Chan WW. Wise SC. Kaufman MD. Ahn YM. Ensinger CL. Haack T. et al. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell, 19, 556–568.
13. Chen LL. Trent JC. Wu EF. Fuller GN. Ramdas L. Zhang W. et al. (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res, 64, 5913–5919.
14. Chi P. Chen Y. Zhang L. Guo X. Wongvipat J. Shamu T. et al. (2010) ETV 1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 467, 849–853.
15. ClinicalTrials identifier: NCT00812240 A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment.
16. ClinicalTrials identifier: NCT01039519 A Study Evaluating STA-9090 in Patients With Metastatic and / or Unresectable Gastrointestinal Stromal Tumor (GIST).
17. ClinicalTrials identifier: NCT01294202 A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST.
18. ClinicalTrials identifier: NCT01404650 Study of Hsp 90 Inhibitor AUY 922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor.
19. ClinicalTrials identifier: NCT01735968 A Dose-finding Study of a Combination of Imatinib and BYL 719 in the Treatment of 3rd Line GIST Patients. 2013.
20. ClinicalTrials identifier: NCT01874665 A Phase 2 Trial of Ponatinib in Patients With Metastatic and / or Unresectable Gastrointestinal Stromal Tumor.
21. ClinicaTrials identifier: NCT01468688 A Dose-finding Study of a Combination of Imatinib and BKM 120 in the Treatment of 3rd Line GIST Patients.
22. Corless CL. Barnett CM. Heinrich MC. (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer, 11, 865–878.
23. Corless CL. McGreevey L. Haley A. Town A. Heinrich MC. (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol, 160, 1567–1572.
24. Corless CL. Schroeder A. Griffith D. Town A. McGreevey L. Harrell P. et al. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol, 23, 5357–5364.
25. Cortes JE. Kantarjian H. Shah NP. Bixby D. Mauro MJ. Flinn I. et al. (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 367, 2075–2088.
26. de Matteo RP. Ballman KV. Antonescu CR. Maki RG. Pisters PW. Demetri GD. et al. (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 373, 1097–1104.
27. Demetri GD. Casali PG. Blay JY. von Mehren M. Morgan JA. Bertulli R. et al. (2009) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 15, 5910–5916.
28. Demetri GD. Garrett CR. Schoffski P. Shah MH. Verweij J. Leyvraz S. et al. (2012) Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res, 18, 3170–3179.
29. Demetri GD. Reichardt P. Kang YK. Blay JY. Rutkowski P. Gelderblom H. et al. (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381, 295–302.
30. Demetri GD. van Oosterom AT. Garrett CR. Blackstein ME. Shah MH. Verweij J. et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 368, 1329–1338.
31. Demetri GD. von Mehren M. Blanke CD. van den Abbeele AD. Eisenberg B. Roberts PJ. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, 472–480.
32. Duensing A. Medeiros F. McConarty B. Joseph NE. Panigrahy D. Singer S. et al. (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene, 23, 3999–4006.
33. Edris B. Willingham SB. Weiskopf K. Volkmer AK. Volkmer JP. Muhlenberg T. et al. (2013) Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A, 110, 3501–3506.
34. Eisenberg BL. Harris J. Blanke CD. Demetri GD. Heinrich MC. Watson JC. et al. (2009) Phase II trial of neoadjuvant / adjuvant imatinib mesylate (IM) for advanced primary and metastatic / recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol, 99, 42–47.
35. Fletcher CD. Berman JJ. Corless C. Gorstein F. Lasota J. Longley BJ. et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 33, 459–465.
36. Floris G. Wozniak A. Sciot R. Li H. Friedman L. van L.T. et al. (2013) A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res, 19, 620–630.
37. George S. Blay JY. Casali PG. Le Cesne A. Stephenson P. Deprimo SE. et al. (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer, 45, 1959–1968.
38. George S. Wang Q. Heinrich MC. Corless CL. Zhu M. Butrynski JE. et al. (2012) Efficacy and safety of regorafenib in patients with metastatic and / or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol, 30, 2401–2407.
39. Heinrich MC. Corless CL. Blanke CD. Demetri GD. Joensuu H. Roberts PJ. et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 24, 4764–4774.
40. Heinrich MC. Corless CL. Demetri GD. Blanke CD. von Mehren M. Joensuu H. et al. (2003 a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21, 4342–4349.
41. Heinrich MC. Corless CL. Duensing A. McGreevey L. Chen CJ. Joseph N. et al. (2003 b) PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299, 708–710.
42. Heinrich M. Griffith D. McKinley A. Patterson J. Presnell A. Ramachandran A. et al. (2012 b) Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 18:4375–4384.
43. Heinrich MC. Maki RG. Corless CL. Antonescu CR. Harlow A. Griffith D. et al. (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 26, 5352–5359.
44. Heinrich MC. Marino-Enriquez A. Presnell A. Donsky RS. Griffith DJ. McKinley A. et al. (2012 a) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther, 11, 1770–1780.
45. Hirota S. Isozaki K. Moriyama Y. Hashimoto K. Nishida T. Ishiguro S. et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577–580.
46. Hohenberger P. Oladeji O. Licht T. Dimitrakopoulou-Strauss A. Jakob J. Pink D. et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 27:15s, 2009 (suppl; abstr 10550). http://meetinglibrary.asco.org/content/33955-65.
47. Jakob J. Mussi C. Ronellenfitsch U. Wardelmann E. Negri T. Gronchi et al. (2013) Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol, 20, 586–592.
48. Janeway K. Kim S. Lodish M. Nosé V. Rustin P. Gaal J. et al. (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumorslacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 108:314–318.
49. Joensuu H. (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39, 1411–1419.
50. Joensuu H. Eriksson M. Sundby HK. Hartmann JT. Pink D. Schutte J. et al. (2012 a) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. JAMA, 307, 1265–1272.
51. Joensuu H. Fletcher C. Dimitrijevic S. Silberman S. Roberts P. Demetri G. (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol, 3, 655–664.
52. Joensuu H. Vehtari A. Riihimaki J. Nishida T. Steigen SE. Brabec P. et al. (2012 b) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Lancet Oncol, 13, 265–274.
53. Kang YK. Ryu MH. Ryoo BY. Kim HJ. Lee JJ. Yoo C. et al. Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and / or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study. J.Clin.Oncol. 31 [ASCO Annual Meeting Proceedings]. http://meeting.ascopubs.org/cgi/content/short/31/18_suppl/LBA10502?rss=1.
54. Killian J. Kim S. Miettinen M. Smith C. Merino M. Tsokos M. et al. (2013) Cancer Discov 3:648–657.
55. Kindler HL. Campbell NP. Wroblewski K. Maki RG. D'Adamo DR. Chow WA. et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol 29: 2011 (suppl; abstr 10009). http://meetinglibrary.asco.org/content/80567-102.
56. Le Cesne A. Blay JY. Bui BN. Bouche O. Adenis A. Domont J. et al. (2010) Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer, 46, 1344–1351.
57. Li D. Ambrogio L. Shimamura T. Kubo S. Takahashi M. Chirieac LR. et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27, 4702–4711.
58. Liegl B. Kepten I. Le C. Zhu M. Demetri GD. Heinrich MC. et al. (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol, 216, 64–74.
59. Lierman E. Smits S. Cools J. Dewaele B. Debiec-Rychter M. Vandenberghe P. (2012) Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia, 26, 1693–1695.
60. Marino-Enriquez A. Ou WB. Cowley G. Luo B. Jonker AH. Mayeda M. et al. (2013) Genome-wide functional screening identifies CDC 37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene [Epub ahead of print].
61. McAuliffe JC. Hunt KK. Lazar AJ. Choi H. Qiao W. Thall P. et al. (2009) A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol, 16, 910–919.
62. MetaGIST (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol, 28, 1247–1253.
63. Miettinen M. Furlong M. Sarlomo-Rikala M. Burke A. Sobin LH. Lasota J. (2001) Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol, 25, 1121–1133.
64. Miettinen M. Lasota J. Sobin LH. (2005) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol, 29, 1373–1381.
65. Miettinen M. Makhlouf H. Sobin LH. Lasota J. (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol, 30, 477–489.
66. Montemurro M. Domont J. Blesius A. Rutkowski P. Roth A. van Moos R. et al. Dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter phase II trial of the SAKK (SAKK 56/07). J Clin Oncol 30, 2012 (suppl; abstr 10033). http://meetinglibrary.asco.org/content/96630-114.
67. Montemurro M. Schoffski P. Reichardt P. Gelderblom H. Schutte J. Hartmann JT. et al. (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer, 45, 2293–2297.
68. Park SH. Ryu MH. Ryoo BY. Im SA. Kwon HC. Lee SS. et al. (2012) Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs, 30, 2377–2383.
69. Patrikidou A. Chabaud S. Ray-Coquard I. Bui BN. Adenis A. Rios M. et al. (2013) Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR 14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol, 24, 1087–1093.
70. Prenen H. Guetens G. De B.G. Debiec-Rychter M. Manley P. Schoffski P. (2006). Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN 107 in gastrointestinal stromal tumor cell lines. Pharmacology, 77, 11–16.
71. Reichardt P. Blay JY. Gelderblom H. Schlemmer M. Demetri GD. Bui-Nguyen B. et al. (2012) Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol, 23, 1680–1687.
72. Rutkowski P. Gronchi A. Hohenberger P. Bonvalot S. Schoffski P. Bauer S. et al. (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol, 20, 2937–2943.
73. Sawaki A. Nishida T. Doi T. Yamada Y. Komatsu Y. Kanda T. et al. (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer, 117, 4633–4641.
74. Soria JC. Massard C. Magne N. Bader T. Mansfield CD. Blay JY. et al. (2009) Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and / or metastatic solid cancers. Eur J Cancer, 45, 2333–2341.
75. Tielen R. Verhoef C. Van C.F. Reyners AK. van der Graaf WT. Bonenkamp JJ. et al. (2013) Surgical management of rectal gastrointestinal stromal tumors. J Surg Oncol, 107, 320–323.
76. Verweij J. Casali PG. Zalcberg J. Le Cesne A. Reichardt P. Blay JY. et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 364, 1127–1134.
77. von Mehren M. Heinrich MC. Joensuu H. Blanke CD. Wehre E. Demetri GD. Follow-up results after 9 years (yrs) of the ongoing, phase II B 2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology 29. 2011. 2011 ASCO Annual Meeting, Abstract 10016.
78. Wardelmann E. Thomas N. Merkelbach-Bruse S. Pauls K. Speidel N. Buttner R. et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol, 6, 249–251.
79. Weisberg E. Manley PW. Breitenstein W. Bruggen J. Cowan-Jacob SW. Ray A. et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, 129–141.
80. Wilhelm SM. Dumas J. Adnane L. Lynch M. Carter CA. Schutz G. et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 129, 245–255.
81. Zhu MJ. Ou WB. Fletcher CD. Cohen PS. Demetri GD. Fletcher JA. (2007) KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene, 26, 6386–6395.